Citric acid cycle intermediates in cardioprotection

Circulation: Cardiovascular Genetics

Volumn 7, Issue 5, 2014, Pages 711-719

  Czibik, Gabor ^a   Steeples, Violetta ^a   Yavari, Arash ^a   Ashrafian, Houman ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardioprotection; Citric acid cycle; Fumaric acid; Nuclear factor (erythroid derived 2) like 2; Oxidationreduction; Reperfusion injury

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE; FLAVINE ADENINE NUCLEOTIDE; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE; HEME OXYGENASE 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXALOACETIC ACID; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROSTAGLANDIN E RECEPTOR 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUCCINIC ACID; SUCCINYL COENZYME A; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CITRIC ACID CYCLE; CLINICAL PRACTICE; ELECTRON TRANSPORT; EXON; GLUCONEOGENESIS; GLYCOLYSIS; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; LOXP SITE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REPERFUSION INJURY; RESPIRATORY CHAIN; ANIMAL; CORONARY ARTERY DISEASE; HEART; METABOLISM; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CITRIC ACID CYCLE; CORONARY ARTERY DISEASE; HEART; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 84911360742     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000220     Document Type: Article

References (91)

1. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-2398
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135
3. Nichols M, Townsend N, Scarborough P, Rayner M. Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009. Eur Heart J. 2013;34:3017-3027
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245
5. van Waes JA, Nathoe HM, de Graaff JC, Kemperman H, de Borst GJ, Peelen LM, et al; Cardiac Health After Surgery (CHASE) Investigators. Myocardial injury after noncardiac surgery and its association with shortterm mortality. Circulation. 2013;127:2264-2271
6. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156
7. Bhattacharya S, Wilson TM, Wojciechowski AP, Volpe CP, Scott J. Hypervariable polymorphism in the APOC3 gene. Nucleic Acids Res. 1991;19:4799
8. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, et al. A mouse model with features of familial combined hyperlipidemia. Science. 1997;275:391-394
9. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ, Dobson GP. Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury. J Appl Physiol (1985). 2007;103:1441-1448
10. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136
11. Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV, et al. Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci. 2008;13:284-301
12. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol. 2007;292:H19-H27
13. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res. 2009;83:247-261
14. Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech. 2010;3:35-38
15. Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99:694-704
16. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, et al. Effects of an intravenous infusion of a potassiumglucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962;9:166-181
17. Morgan HE, Henderson MJ, Regen DM, Park CR. Regulation of glucose uptake in muscle. I. The effects of insulin and anoxia on glucose transport and phosphorylation in the isolated, perfused heart of normal rats. J Biol Chem. 1961;236:253-261
18. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fattyacid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789
19. Jonassen AK, Sack MN, Mjøs OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-1198
20. Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG. Glucose-insulin-potassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2000;278:H595-H603
21. Angelos MG, Murray HN, Gorsline RT, Klawitter PF. Glucose, insulin and potassium (GIK) during reperfusion mediates improved myocardial bioenergetics. Resuscitation. 2002;55:329-336
22. Rogers WJ, Stanley AW Jr, Breinig JB, Prather JW, McDaniel HG, Moraski RE, et al. Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin-potassium infusion. Am Heart J. 1976;92:441-454
23. Howell NJ, Ashrafian H, Drury NE, Ranasinghe AM, Contractor H, Isackson H, et al. Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial. Circulation. 2011;123:170-177
24. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65
25. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, et al. Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation. 1972;45:1160-1175
26. Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation. 2008;117:2523-2533
27. Taegtmeyer H. Metabolic responses to cardiac hypoxia. Increased production of succinate by rabbit papillary muscles. Circ Res. 1978;43:808-815
28. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell. 2005;8:143-153
29. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14:2231-2239
30. Czibik G. Complex role of the HIF system in cardiovascular biology. J Mol Med (Berl). 2010;88:1101-1111
31. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20:524-537
32. Ashrafian H, Czibik G, Bellahcene M, Aksentijevic D, Smith AC, Mitchell SJ, et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012;15:361-371
33. Krebs HA. The citric acid cycle and the Szent-Györgyi cycle in pigeon breast muscle. Biochem J. 1940;34:775-779
34. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385-388
35. Fan J, Kamphorst JJ, Rabinowitz JD, Shlomi T. Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive isocitrate dehydrogenase (IDH) flux. J Biol Chem. 2013;288:31363-31369
36. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148:1132-1144
37. Brunengraber H, Roe CR. Anaplerotic molecules: current and future. J Inherit Metab Dis. 2006;29:327-331
38. Des Rosiers C, Labarthe F, Lloyd SG, Chatham JC. Cardiac anaplerosis in health and disease: food for thought. Cardiovasc Res. 2011;90: 210-219
39. LaNoue K, Nicklas WJ, Williamson JR. Control of citric acid cycle activity in rat heart mitochondria. J Biol Chem. 1970;245:102-111
40. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011;14:443-451
41. Støttrup NB, Løfgren B, Birkler RD, Nielsen JM, Wang L, Caldarone CA, et al. Inhibition of the malate-aspartate shuttle by pre-ischaemic aminooxyacetate loading of the heart induces cardioprotection. Cardiovasc Res. 2010;88:257-266
42. Fromm H. Determination of dissociation constants of coenzymes and abortive ternary complexes with rabbit muscle lactate dehydrogenase from fluorescence measurements. J Biol Chem. 1963;238:2938-2944
43. Snaith CD, Wright G, Lofkin M. The effects of aspartate and 2-oxoglutarate upon glycolytic energy metabolites and mechanical recovery following global ischaemia in isolated rat hearts. J Mol Cell Cardiol. 1992;24:305-315
44. Pisarenko OI, Studneva IM, Shulzhenko VS, Korchazhkina OV, Kapelko VI. Substrate accessibility to cytosolic aspartate aminotransferase improves posthypoxic recovery of isolated rat heart. Biochem Mol Med. 1995;55:138-148
45. Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol. 2012;93:302-308
46. Penney DG, Cascarano J. Anaerobic rat heart. Effects of glucose and tricarboxylic acid-cycle metabolites on metabolism and physiological performance. Biochem J. 1970;118:221-227
47. Needham DM. A quantitative study of succinic acid in muscle: glutamic and aspartic acids as precursors. Biochem J. 1930;24:208-227
48. Hochachka PW, Owen TG, Allen JF, Whittow GC. Multiple end products of anaerobiosis in diving vertebrates. Comp Biochem Physiol B. 1975;50:17-22
49. Kiss G, Konrad C, Pour-Ghaz I, Mansour JJ, Németh B, Starkov AA, et al. Mitochondrial diaphorases as NAD? donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition. FASEB J. 2014;28:1682-1697
50. Hohl C, Oestreich R, Rösen P, Wiesner R, Grieshaber M. Evidence for succinate production by reduction of fumarate during hypoxia in isolated adult rat heart cells. Arch Biochem Biophys. 1987;259:527-535
51. Peuhkurinen KJ, Takala TE, Nuutinen EM, Hassinen IE. Tricarboxylic acid cycle metabolites during ischemia in isolated perfused rat heart. Am J Physiol. 1983;244:H281-H288
52. Sanborn T, Gavin W, Berkowitz S, Perille T, Lesch M. Augmented conversion of aspartate and glutamate to succinate during anoxia in rabbit heart. Am J Physiol. 1979;237:H535-H541
53. Wiesner RJ, Deussen A, Borst M, Schrader J, Grieshaber MK. Glutamate degradation in the ischemic dog heart: contribution to anaerobic energy production. J Mol Cell Cardiol. 1989;21:49-59
54. Pietersen HG, Langenberg CJ, Geskes G, Soeters PB, Wagenmakers AJ. Glutamate metabolism of the heart during coronary artery bypass grafting. Clin Nutr. 1998;17:73-75
55. Jessen ME, Kovarik TE, Jeffrey FM, Sherry AD, Storey CJ, Chao RY, et al. Effects of amino acids on substrate selection, anaplerosis, and left ventricular function in the ischemic reperfused rat heart. J Clin Invest. 1993;92:831-839
56. Langenberg CJ, Pietersen HG, Geskes G, Wagenmakers AJ, Lange SD, Schouten HJ, et al. The effect of glutamate infusion on cardiac performance is independent of changes in metabolism in patients undergoing routine coronary artery bypass surgery. Clin Sci (Lond). 2001;101:573-580
57. Lomivorotov VV, Efremov SM, Shmirev VA, Ponomarev DN, Lomivorotov VN, Karaskov AM. Glutamine is cardioprotective in patients with ischemic heart disease following cardiopulmonary bypass. Heart Surg Forum. 2011;14:E384-E388
58. Lomivorotov VV, Efremov SM, Shmirev VA, Ponomarev DN, Svyatchenko AV, Deryagin MN, et al. Does glutamine promote benefits for patients with diabetes mellitus scheduled for cardiac surgery? Heart Lung Circ. 2013;22:360-365
59. Kasumov T, Sharma N, Huang H, Kombu RS, Cendrowski A, Stanley WC, et al. Dipropionylcysteine ethyl ester compensates for loss of citric acid cycle intermediates during post ischemia reperfusion in the pig heart. Cardiovasc Drugs Ther. 2009;23:459-469
60. Okere IC, McElfresh TA, Brunengraber DZ, Martini W, Sterk JP, Huang H, et al. Differential effects of heptanoate and hexanoate on myocardial citric acid cycle intermediates following ischemia-reperfusion. J Appl Physiol (1985). 2006;100:76-82
61. Stanley WC, Kivilo KM, Panchal AR, Hallowell PH, Bomont C, Kasumov T, et al. Post-ischemic treatment with dipyruvyl-acetyl-glycerol decreases myocardial infarct size in the pig. Cardiovasc Drugs Ther. 2003;17:209-216
62. Pearl JM, Hiramoto J, Laks H, Drinkwater DC Jr, Chang PA. Fumarateenriched blood cardioplegia results in complete functional recovery of immature myocardium. Ann Thorac Surg. 1994;57:1636-1641
63. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14:1067-1076
64. Hamel D, Sanchez M, Duhamel F, Roy O, Honore JC, Noueihed B, Zhou T, Nadeau-Vallee M, Hou X, Lavoie JC, Mitchell G, Mamer OA, Chemtob S et al. G-protein-coupled receptor 91 and succinate are key contributors in neonatal postcerebral hypoxia-ischemia recovery. Arterioscler Thromb Vasc Biol. 2014;34:285-293
65. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7:77-85
66. Hewitson KS, Liénard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem. 2007;282:3293-3301
67. Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem. 2007;282:4524-4532
68. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol. 2007;27:3282-3289
69. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46:2116-2124
70. Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res. 2008;77:463-470
71. Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxiainducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008;118:166-175
72. Laplante A, Vincent G, Poirier M, Des Rosiers C. Effects and metabolism of fumarate in the perfused rat heart. A 13C mass isotopomer study. Am J Physiol. 1997;272(1 Pt 1):E74-E82
73. Vincent G, Comte B, Poirier M, Rosiers CD. Citrate release by perfused rat hearts: a window on mitochondrial cataplerosis. Am J Physiol Endocrinol Metab. 2000;278:E846-E856
74. Wikström BG, Ronquist G, Waldenström A. Dynamics of myocardial metabolism in the preconditioned porcine heart studied using continuous microdialysis. Eur Heart J. 1995;16:563-569
75. Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20:511-523
76. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107
77. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13:1713-1748
78. Frizzell N, Lima M, Baynes JW. Succination of proteins in diabetes. Free Radic Res. 2011;45:101-109
79. Ternette N, Yang M, Laroyia M, Kitagawa M, O'Flaherty L, Wolhulter K, et al. Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013;3:689-700
80. Gardner PR. Aconitase: sensitive target and measure of superoxide. Methods Enzymol. 2002;349:9-23
81. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res. 2001;89:168-173
82. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, et al. Gene therapy strategy for long-term myocardial protection using adenoassociated virus-mediated delivery of heme oxygenase gene. Circulation. 2002;105:602-607
83. Fujimoto H, Ohno M, Ayabe S, Kobayashi H, Ishizaka N, Kimura H, et al. Carbon monoxide protects against cardiac ischemia-reperfusion injury in vivo via MAPK and Akt-eNOS pathways. Arterioscler Thromb Vasc Biol. 2004;24:1848-1853
84. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol. 2000;278:H643-H651
85. Yoshida T, Maulik N, Ho YS, Alam J, Das DK. H(mox-1) constitutes an adaptive response to effect antioxidant cardioprotection: A study with transgenic mice heterozygous for targeted disruption of the Heme oxygenase-1 gene. Circulation. 2001;103:1695-1701
86. Vulapalli SR, Chen Z, Chua BH, Wang T, Liang CS. Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol. 2002;283:H688-H694
87. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477:225-228
88. Vreman HJ, Lee OK, Stevenson DK. In vitro and in vivo characteristics of a heme oxygenase inhibitor: ZnBG. Am J Med. Sci. 1991;302:335-341
89. Czibik G, Sagave J, Martinov V, Ishaq B, Sohl M, Sefland I, et al. Cardioprotection by hypoxia-inducible factor 1 alpha transfection in skeletal muscle is dependent on haem oxygenase activity in mice. Cardiovasc Res. 2009;82:107-114
90. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082-4090
91. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell. 2013;51:236-248.